VA Cooperative Study of the Efficacy of Hepatitis Immune Serum Globulin for the Prevention or Modification of Post-Transfusion Hepatitis (VA2-TAH)

HLB01031313a

VA2-TAH

(NANB-TAH) Natural History Study of Non-A, Non-B Post-Transfusion Hepatitis (NANB-TAH)

False

Released

True

True

Coded

False

Clinical Trial

Open BioLINCC Study

Adult

2013-06-21

2013-06-21

2013-06-20

2023-02-07

1972 – 1976

DBDR

Transfusion Medicine

non-HIV

non-COVID

0

0

No

No

No

No

Yes

No

Blood Transfusion
Hepatitis, Viral, Human

This double blind, randomized, controlled trial was designed to test the efficacy of hepatitis B immune serum globulin (HBIG) for the prevention or modification of post-transfusion hepatitis (PTH).

In the mid-1960’s, PTH was a major health problem in the US. Approximately 30,000 cases occurred each year, resulting in 1,500 to 3,000 deaths annually. The incidence of HBs Ag-associated hepatitis declined dramatically after 1973 with the institution of routine screening of donor blood by radioimmunoassay techniques, although no change in the incidence of antigen-negative hepatitis had occurred. An earlier randomized, double-blind clinical trial had been conducted in 11 Veterans Administration (VA) hospitals between 1969 and 1973 to evaluate the efficacy of immune serum globulin (ISG) in comparison to placebo as prophylaxis against post-transfusion hepatitis. The results indicated that ISG prohibited the development of PTH in specific circumstances. ISG led to a significant decrease in the incidence of icteric type non-B hepatitis among patients who had been transfused with three or more units of commercial blood, but had little effect on the hepatitis that developed among those that received volunteer donor blood (1). Since hepatitis B represented 22% of cases of PTH, a second randomized study was undertaken immediately on conclusion of the first one to compare the efficacy of ISG with HBIG.

A total of 986 patients were enrolled between 1973 and 1975 at 6 Veterans Administration hospitals. A subset of this cohort was subsequently recruited into the Natural History Study of Non-A, Non-B Post Transfusion Hepatitis (NANB-TAH) that also has data and biospecimens available. The VA2-TAH cohort can be longitudinally linked to the NANB-TAH study data.

Eighteen of the enrolled subjects had tested positive for pre-existing Hepatitis B surface antigen (HBsAg). They were not randomized and were given ISG. Of the remainder, 482 were randomized to ISG and 486 to HBIG. Patients were eligible for the trial if they received one or more transfusions of whole blood or packed cells, did not meet any of the exclusion criteria, and could be randomized and receive their first injection within 120 hours of the first transfusion. Exclusion criteria included the likelihood of repeated transfusions in the next six months, transfusions or gamma globulin products within the previous six months, serious illnesses limiting survival, previous participation in this trial, and unwillingness to sign the informed consent. Patients were randomized and received their first injection within 120 hours of transfusion. They were then followed at two-week intervals for six months and then at weeks 35, 44, and 52. Patients with alanine aminotransferase value of >40 Karmen Units (KU) were also tested for bilirubin, aspartate aminotransferase and alkaline phosphatase and followed at weekly intervals for a minimum of four weeks (intensive visits). The diagnosis of hepatitis was made using a scoring algorithm (Protocol Appendix I).

Pre-transfusion and donor blood samples were obtained from the Blood Bank. All blood samples were tested for HBsAg and antibody to HBsAg (anti-HBs). All donor blood was pre-screened for HBsAg and when possible retested for HBsAg and anti-HBs. Hepatitis B was defined as the development of HBsAg or anti-HBs in patients that met the definition of acute hepatitis. Selected samples were also tested for anti-HBs and for the antibody to Hepatitis B core antigen (HBc).

PTH was diagnosed in 11.0% of the HBIG group (53/482) compared to 14.2% of the ISG group (69/486), p = 0.13 (2,3). Hepatitis B developed in 4 of 969 patients that received ISG or HBIG although all donor blood was screened and found to be HBsAg–negative by radioimmunoassay. Subsequent testing of recipient and donor blood samples for anti-HBc demonstrated the importance of anti-HBc as an indicator of hepatitis B infection and supported the hypothesis that high-titer anti-HBc positive blood is infectious (4).

Serum